3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
5
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Interventions
Cisplatin
30
Radiotherapy
24
pembrolizumab
21
Cetuximab
21
Docetaxel
13
Fluorouracil
12
Radiotherapy, Intensity-Modulated
10
Paclitaxel
9
Radiation
8
Nivolumab
7
Everolimus
7
Carboplatin
7
Oxaliplatin
6
Gemcitabine
5
Surgical Procedures, Operative
4
Radiosurgery
4
Magnetic Resonance Spectroscopy
4
Gefitinib
4
Erlotinib Hydrochloride
4
Amifostine
4
Pemetrexed
3
Filgrastim
3
Capecitabine
3
Bleomycin
3
Biopsy
3
zalutumumab
2
spartalizumab
2
pegfilgrastim
2
niraparib
2
durvalumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Head and Neck Neoplasms
×
Platinum Compounds
×
Clear all
NCT04428333
2024-10-09
INDUCE-4
GlaxoSmithKline
Phase 3
Terminated
117 enrolled
33 charts